Explore Innovative Cell Therapies Today

TRANSFORMING T CELL THERAPIES

“Current cell therapies often rely on patient-specific manufacturing, resulting in high costs, long production times, and variable quality. Repairon Immuno takes a fundamentally different approach.”

Our Company Profile

Repairon Immuno is a startup with the mission to enhance existing and emerging CART therapies. To achieve this goal, we take advantage of worldwide licensed induced Pluripotent Stem Cell (iPSC) line, which is being validated in an European clinical trial. This cell line in combination with our proprietary, scalable, GMP-compliant differentiation platform as well as proprietary gene editing designs will enable us to generate never-done-before types of cell drug products to tune T cells and transform CART cell therapies, such as in vivo CART.

A Platform for Next-Generation Immune Cells

Current cell therapies often rely on patient-specific manufacturing, resulting in high costs, long production times, and variable quality. Repairon Immuno takes a fundamentally different approach.

Induced Pluripotent Stem Cells (iPSCs) are somatic human cells that are reprogrammed into a stem cell state, giving them the unique ability to generate virtually any specialized cell type in the body, including immune cells. For clinical medicine, this is transformative. Unlike conventional cell therapies that must be manufactured individually for each patient, iPSCs provide a renewable, standardized starting material.

A single, well-characterized cell line can produce large quantities of identical therapeutic cells with consistent quality, enabling scalable manufacturing, improved safety control, and significantly lower costs. This shift — from bespoke to off-the-shelf production — makes advanced cell therapies faster to deliver, more reliable, and accessible to far more patients. At Repairon Immuno, iPSC technology forms the foundation of our platform, allowing us to engineer next-generation immune cell therapies designed for precision, scalability, and real-world clinical impact.

Why iPSCs?

induced Pluripotent Stem Cells provide:

— An unlimited & renewable cell source

— Precise genetic engineering before differentiation

— High product homogeneity

— Scalability for GMP manufacturing

— Off-the-shelf therapeutic potential

Where we work

Our Laboratories

Helmholtz Zentrum München, Ingolstädter Landstraße 1, 85764 Munich
Life Science Factory

The Life Science Factory Munich on the Helmholtz Pioneer Campus
Cell Production

Manufacturing Regulatory Cells from induced Pluripotent Stem Cells (iPSCs)
Munich

Munich is one of Europe's leading, most dynamic startup hubs, characterized by a strong focus on deep tech, AI, mobility, and life sciences